Form 4: Sellas Life Sciences Executive Dragan Cicic Awarded Stock and Options
SEC Form 4 Filing
Sellas Life Sciences Group's SVP, Chief Development Officer, Dragan Cicic, received a grant of restricted stock units and stock options.
Summary
- Dragan Cicic, SVP and Chief Development Officer at Sellas Life Sciences Group, was granted 113,000 restricted stock units and 81,300 restricted stock units on January 10, 2025.
- The 113,000 restricted stock units vest in four equal installments starting December 1, 2025, and annually thereafter.
- The 81,300 restricted stock units vest in full on December 1, 2025.
- Cicic also received stock options for 169,500 shares with an exercise price of $0.9525.
- These options vest over 48 months, with 25% vesting one year from the grant date and the remainder vesting monthly over the following 36 months.
- All vesting is contingent on continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive for aligning executive interests with company performance. There are no indications of negative sentiment.
Positives
- The grants of restricted stock units and stock options align Dragan Cicic's interests with the long-term success of Sellas Life Sciences.
- The vesting schedules for the stock units and options encourage continued service and commitment from the executive.
Risks
- The vesting of the stock units and options is contingent on continued employment, which could be a risk if the executive leaves the company before full vesting.
Industry Context
This type of equity compensation is common practice for incentivizing key executives in the biotechnology and pharmaceutical industries.
Comparison to Industry Standards
- Equity grants, including restricted stock units and stock options, are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules that are contingent on continued employment are also typical to ensure long-term commitment from key personnel.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign of incentivizing management.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of grant for restricted stock units and stock options. |
| 12/01/2025 | First vesting date for 25% of the 113,000 restricted stock units and full vesting date for the 81,300 restricted stock units. |
| 01/10/2035 | Expiration date for the stock options. |
| 01/14/2025 | Date of signature for the SEC Form 4 filing. |
Keywords
stock options, restricted stock units, executive compensation, insider trading, equity awards, vesting, SELLAS Life Sciences, SLS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.